Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) Debt to Equity (2017 - 2021)

Historic Debt to Equity for Sunshine Biopharma (SBFM) over the last 5 years, with Q4 2021 value amounting to $8.98.

  • Sunshine Biopharma's Debt to Equity rose 100317.31% to $8.98 in Q4 2021 from the same period last year, while for Dec 2021 it was $8.98, marking a year-over-year increase of 100317.31%. This contributed to the annual value of $8.98 for FY2021, which is 100317.31% up from last year.
  • Sunshine Biopharma's Debt to Equity amounted to $8.98 in Q4 2021, which was up 100317.31% from -$2.73 recorded in Q3 2021.
  • Sunshine Biopharma's Debt to Equity's 5-year high stood at $8.98 during Q4 2021, with a 5-year trough of -$5.57 in Q4 2018.
  • For the 5-year period, Sunshine Biopharma's Debt to Equity averaged around -$0.05, with its median value being -$0.99 (2020).
  • Its Debt to Equity has fluctuated over the past 5 years, first plummeted by 390880.59% in 2018, then surged by 100317.31% in 2021.
  • Quarter analysis of 5 years shows Sunshine Biopharma's Debt to Equity stood at -$0.14 in 2017, then tumbled by 3908.81% to -$5.57 in 2018, then surged by 99.33% to -$0.04 in 2019, then plummeted by 2580.8% to -$0.99 in 2020, then soared by 1003.17% to $8.98 in 2021.
  • Its Debt to Equity was $8.98 in Q4 2021, compared to -$2.73 in Q3 2021 and -$2.35 in Q2 2021.